Fibroblast‐growth‐factor‐23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes
Abstract Aims This study aimed to assess plasma fibroblast growth factor 23 (FGF23) in patients with heart failure with preserved ejection fraction (HFpEF) and its relation to inflammation, renal function, clinical and imaging characteristics, exercise capacity, and prognosis. Methods and results We...
Main Authors: | Prathap Kanagala, Jayanth R. Arnold, Jamal N. Khan, Anvesha Singh, Gaurav S. Gulsin, Mohamed Eltayeb, Pankaj Gupta, Iain B. Squire, Gerry P. McCann, Leong L. Ng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13020 |
Similar Items
-
Plasma P‐selectin is a predictor of mortality in heart failure with preserved ejection fraction
by: Prathap Kanagala, et al.
Published: (2021-06-01) -
Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction – implications for clinical trials
by: Prathap Kanagala, et al.
Published: (2018-01-01) -
Fibroblast growth factor-23 and hypophosphatemia in chronic obstructive pulmonary disease patients
by: Elsammak Mohamed Y., et al.
Published: (2012-01-01) -
Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
by: Mireille El Ters, et al.
Published: (2021-04-01) -
Assessment of fibroblast growth factor 23 in relation to peripheral arterial disease in type 2 diabetes mellitus
by: Mohamed R Halawa, et al.
Published: (2019-01-01)